108 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Purchased by Ashton Thomas Private Wealth LLC

Ashton Thomas Private Wealth LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 108 shares of the biopharmaceutical company’s stock, valued at approximately $26,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC raised its position in shares of Alnylam Pharmaceuticals by 572.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 168 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 143 shares during the period. Altitude Crest Partners Inc. purchased a new stake in Alnylam Pharmaceuticals in the first quarter valued at $30,000. V Square Quantitative Management LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $52,000. GAMMA Investing LLC grew its holdings in shares of Alnylam Pharmaceuticals by 97.2% during the 2nd quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock worth $101,000 after purchasing an additional 205 shares during the period. Finally, Prestige Wealth Management Group LLC increased its position in shares of Alnylam Pharmaceuticals by 69.8% during the 1st quarter. Prestige Wealth Management Group LLC now owns 472 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 194 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, CEO Yvonne Greenstreet sold 8,301 shares of the company’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 32,450 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 24th. The shares were sold at an average price of $220.69, for a total value of $7,161,390.50. Following the transaction, the director now directly owns 136 shares in the company, valued at $30,013.84. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 103,148 shares of company stock valued at $25,658,824. 1.50% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Stock Up 1.5 %

ALNY stock opened at $274.46 on Wednesday. The business has a 50 day moving average price of $258.84 and a 200 day moving average price of $195.93. The stock has a market cap of $34.72 billion, a price-to-earnings ratio of -101.19 and a beta of 0.38. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $287.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.74) by $0.61. The company had revenue of $659.83 million for the quarter, compared to analysts’ expectations of $447.22 million. The firm’s quarterly revenue was up 107.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($2.21) EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.73 EPS for the current year.

Analysts Set New Price Targets

A number of research firms have commented on ALNY. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 4th. Citigroup increased their price objective on shares of Alnylam Pharmaceuticals from $291.00 to $342.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. UBS Group boosted their target price on Alnylam Pharmaceuticals from $253.00 to $288.00 and gave the company a “buy” rating in a research report on Friday, June 28th. Morgan Stanley upped their price target on Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $400.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, August 30th. Seven investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $279.14.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.